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Abstract Glycated hemoglobin A1c (HbA1c) indicates the
percentage of total hemoglobin that is bound by glucose,
produced from the nonenzymatic chemical modification by
glucose of hemoglobin molecules carried in erythrocytes.
HbA1c represents a surrogate marker of average blood
glucose concentration over the previous 8 to 12 weeks, or
the average lifespan of the erythrocyte, and thus represents a
more stable indicator of glycemic status compared with
fasting glucose. HbA1c levels are genetically determined, with
heritability of 47% to 59%. Over the past few years, inroads
into understanding genetic predisposition by glycemic and
nonglycemic factors have been achieved through genome-
wide analyses. Here I review current research aimed at
discovering genetic determinants of HbA1c levels, discussing
insights into biologic factors influencing variability in the
general and diabetic population, and across different ethnic-
ities. Furthermore, I discuss briefly the relevance of findings
for diabetes monitoring and diagnosis.
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Introduction
Type 2 diabetes is a common metabolic disorder defined by
the presence of markedly elevated levels of plasma glucose
[1], which arise from dysregulations in the complex
interplay between pancreatic β-cell function and insulin
sensitivity in hepatic and skeletal muscle cells. Genetic
association studies have recently revealed nearly 40
robustly replicated loci for type 2 diabetes [2]. Parallel,
high-powered genome-wide analyses of quantitative glyce-
mic traits [3–6, 7￿￿] have provided alternative insights into
the function of these loci, which are informing our
understanding of disease pathophysiology.
Glycated hemoglobin A1c (HbA1c), or the percentage of
total hemoglobin that is bound by glucose, provides a better
estimate of average glycemia than routine determinations of
blood glucose concentration, and is the most widely used
index of chronic glycemia [8, 9]. It results from the
nonenzymatic chemical modification of hemoglobin mole-
cules carried in erythrocytes by glucose. The glycation
process involves the nonenzymatic attachment of glucose to
the NH-terminal N-terminal valine and internal lysine
amino groups of hemoglobin [10]. The glycation reaction
is mostly irreversible, so that the concentration of HbA1c is
a function of the concentration of glucose to which the
erythrocytes are exposed over their lifespan (120 days on
average). HbA1c therefore represents a surrogate marker of
average blood glucose concentration over the previous 8 to
12 weeks, thus representing a longer-term indicator of
glycemic status compared with fasting glucose [11].
HbA1c levels are better predictors than fasting glucose of
the development of long-term complications in type 1 and
type 2 diabetes [12], and higher levels in the subdiabetic
range have been shown to predict type 2 diabetes risk and
cardiovascular disease [13, 14]. For these reasons an
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revision of the diagnostic criteria for diabetes, recommend-
ing that HbA1c may be a better means of diagnosing
diabetes than measures of glucose (fasting and/or post-
challenge) and that it be adopted as a diagnostic criterion
for diabetes [15].
The heritability of HbA1c levels is relatively high (47%
to 59%) when compared with fasting glucose (34% to 36%)
or glucose level 2-hour post-oral glucose tolerance test
(OGTT) (33%) [16, 17], and thus amenable to genetic
analysis. Here I review current research aimed at discover-
ing genetic determinants of HbA1c levels, discussing
insights into biologic factors influencing variability in the
general and diabetic population, and across different
ethnicities. Furthermore, I discuss the relevance of findings
for diabetes monitoring and diagnosis.
The First Generation of Genetic Studies: Linkage Scans
and Candidate Gene Association Studies
There is a relative paucity of published reports on linkage and
candidate gene association studies for HbA1c levels. The
Framingham Heart Study conducted a genome-wide search
for diabetes-related genes using measures of glycemia as
quantitative traits (20-year mean fasting glucose, current
fasting glucose, and HbA1c). A total of 771 men and women
from 330 pedigrees from the 5th Offspring Study exam cycle
(1991–1995) had information on HbA1c levels and were
typed at 401 microsatellite markers (at an average spacing of
10 cM). Peak evidence for linkage to HbA1c levels was on
the long arm of chromosome 1 at 187 cM (multipoint
logarithm of the odds score, 2.81), in a model accounting for
age, cigarette smoking, alcohol and estrogen use, physical
activity, and body mass index. The same broad chromosomal
region had been reported as having evidence for linkage for
type 2 diabetes and quantitative fasting traits.
Among the first candidate gene studies, Shima et al. [18]
tested the association of variants in the calpain-10 gene
(CAPN10)g e n e —a candidate gene for type 2 diabetes
originally reported in Mexican Americans—with several
metabolic traits in 286 unselected Japanese subjects. They
found one single nucleotide polymorphism (SNP-19) asso-
ciated with higher body mass index and HbA1c levels at the
nominal level under the dominant model (P=0.003 and P=
0.024, respectively), indicating a contribution of CAPN10
variants to mild obesity and glucose intolerance in Japanese.
More recently, Krízová et al. [19] tested associations of
variants at two candidate genes of insulin resistance and type
2 diabetes mellitus, adiponectin (ADIPOQ) and resistin
(RETN), in individuals of European ancestry. They geno-
typed SNPs 45T>G and 276G>T in ADIPOQ and 62G>A
and −180C>G in RETN in patients with obesity, anorexia
nervosa, and in control healthy normal-weight women, and
tested associations with serum concentrations of these
hormones and measures of insulin sensitivity and metabolic
traits, including tumor necrosis factor-α, insulin, cholesterol,
HbA1c, and blood glucose levels. They found significant
associations of SNP ADP+276G>T allele with higher
cholesterol levels in patients with anorexia, higher adipo-
nectin concentrations in obese patients, and lower HbA1c
levels in normal women. SNP of the resistin gene 62G>A
was associated with lower HbA1c in normal women and
higher cholesterol concentrations in the obese group.
However, neither of these two associations at CAPN10 and
RETN was replicated in further, high-powered genome-wide
association studies (GWAS).
Locus Discovery through GWAS in Healthy Individuals
The advent of genome-wide SNP arrays and imputation-
based meta-analysis has provided a robust statistical
framework for discovery and replication, and boosted locus
discovery revealing a wealth of genetic loci associated with
disease and quantitative end points. GWAS of fasting
glucose levels led to the identification of associations with
HbA1c at three loci (G6PC2, MTNR1B, and GCK)[ 4, 5,
20–25]. The association of MTNR1B with HbA1c was
furthermore replicated in 3210 unrelated Chinese Hans
from Beijing [26], whereas to date no GWAS have been
reported in non-European samples.
In the first GWAS of HbA1c levels, Paré et al. [27￿]
investigated 337,343 SNPs in 14,618 healthy women of
European ancestry from the Women’s Genome Health
Study, and validated their findings in 455 nondiabetic
Caucasian participants recruited from the Boston metropol-
itan area. They detected four loci with significant associa-
tion at the genome-wide level of 10
−6. Of these, three were
previously associated with type 2 diabetes or glycemic end
points (GCK, SLC30A8, and G6PC2)[ 20, 21, 23, 25, 28]
and in people free of diabetes. The fourth mapped to an
intron in HK1, and was a novel locus.
Investigators of the MAGIC recently completed the
largest to date meta-analysis of HbA1c levels [7￿￿]. The
genome-wide discovery set used in this study included
approximately 2.5 million genotyped and imputed autoso-
mal SNPs genotyped in 35,920 participants, a sample size
that has 80% power to detect SNPs explaining 0.12% of
the trait variance at the genome-wide significant threshold
of P=5×10
−8. The analysis confirmed a strong statistical
support at GCK, G6PC2/ABCB11, MTNR1B,a n dHK1,
confirming previous reports [5, 21–25, 27￿]. Furthermore,
novel evidence for association was detected at six loci (in
or near FN3K, HFE, TMPRSS6, ATP11A/TUBGCP3,
ANK1, and SPTA1).
Curr Diab Rep (2011) 11:562–569 563In parallel, Franklin et al. [29] completed a GWAS meta-
analysis of glycated hemoglobin levels in 1782 healthy
individuals from three genetically isolated populations: the
Orkney Isles in the north of Scotland, the Dalmatian islands
of Vis, and Korčula in Croatia. They reported a genome-
wide significant association at an intronic variant in the
TCF7L2 gene, the strongest common genetic risk factor for
type 2 diabetes. An association at the same locus was also
reported by Karns et al. [30] in a small sample of 843
individuals.
Associations with Correlated Metabolic
and Hematologic Traits and Disease Provide Insights
into Biologic Determinants of HbA1c Variance
In addition to ambient glycemia, it is known that medical
conditions that change erythrocyte turnover, hereditary
anemias, and iron storage disorders can influence the
variability of HbA1c in populations [31]. The former include
hemolytic anemias, chronic malaria, major blood loss, or
blood transfusion; the latter are caused by rare causative
mutations in genes involved in erythrocyte membrane
stability, hemoglobin function, and glucose sensing and
membrane transport in erythrocytes. It is thus of interest to
assess if genetic variation segregating at high frequencies in
the population, and causing subtler variation in these
parameters, might also affect HbA1c.F u r t h e r m o r e ,i ti s
important to establish whether variation due to nonglycemic
factors affects the utility of HbA1c in clinical practice.
Evidence from GWAS (Table 1) supports the notion that
common variants might affect HbA1c levels through their
effects on glucose levels and also through erythrocyte
biology. A first evidence for this came from the study of
Paré et al. [27￿], who identified associations at four loci,
including GCK, SLC30A8, G6PC2, and HK1. HK1 encodes
the enzyme hexokinase, which catalyzed the first step in
glycolysis and thus represents a likely candidate for the
control of glucose metabolism. HK1 is the only isoform that
is essential for red blood cell glucose metabolism [32], and
is the predominant form among the four isozymes of the
hexokinase family (HK1, HK2, HK3, and glucokinase). It
is expressed in the vast majority of cells and tissues,
including cells that are strictly dependent on glucose uptake
for their metabolic needs [33]. In humans, rare nonsynon-
ymous substitutions in the active site of HK1 and intragenic
deletions have been shown to cause HK1 enzymatic
deficiency associated with autosomal-recessive severe non-
spherocytic hemolytic anemia [33–36]. The downeast
anemia mice display HK1 deficiency and a similar anemic
phenotype [32].
These observations led Bonnefond et al. [37￿]t o
postulate that HK1 genetic variation may indirectly alter
HbA1c measurements by generating a proanemic state, and
independently of ambient blood glucose levels. They
assessed the impact of the sentinel SNP at HK1 on HbA1c,
glucose control-related traits (fasting- and 2-hour post-
OGTT–related parameters), type 2 diabetes risk, and red
blood cell–related parameters in Europeans. Surprisingly,
the most associated SNP at this locus showed no associa-
tion with any other markers of glucose control, whereas it
was significantly associated with hemoglobin levels, he-
matocrit, and anemia.
The subsequent study by the MAGIC investigators [7￿￿]
provided additional evidence of HbA1c-associated loci with
no evidence for association with glucose-control traits. Of
the 10 loci associated with HbA1c at the genome-wide
level, three had significant evidence for association of the
HbA1c-raising allele with fasting glucose and β-cell
function (GCK, MTNR1B, and G6PC2) in this and previous
studies, and GCK also with 2-hour glucose [3–6, 24, 25,
27￿, 38, 39]. Two of them (GCK and MTNR1B) were also
associated with type 2 diabetes [3]. For the remaining seven
we found no evidence for association with glycemic traits
and diabetes, nor with insulin levels, despite adequate
power. Of these, associations at the HFE and TMPRSS6
loci mapped to known functional variants in two comple-
mentary and directionally consistent pathways [40] and
were associated with quantitative hematologic traits [7￿￿,
41, 42]. At HFE the A allele at rs1800562 (Cys262Tyr),
which is responsible for hereditary hemochromatosis (MIM
235200), was associated with lower levels of HbA1c, rather
than the higher levels one would predict from epidemio-
logic observations of the increased HFE mutation preva-
lence in patients with type 2 diabetes [43, 44]. The
reciprocal observation was seen for TMPRSS6, where the
A allele at SNP rs855791 (Val736Ala) was associated with
lower hemoglobin levels and higher HbA1c levels.
Three additional loci (SPTA1, ANK1, and including HK1
discussed earlier) showed suggestive associations with
erythrocyte indexes, and rare variants at these loci cause
hereditary anemias [45, 46]. We postulated that functional
variants at HK1 may affect a potential dissociation between
ambient plasma glucose and intracellular cytoplasmic glu-
cose, and that the hemoglobin-lowering variant may affect
the overall percent of HbA1c through an increased glucose/
hemoglobin molar ratio, which in turn could increase the rate
of hemoglobin that is glycated at a given glucose level. We
further postulated a possible role of erythrocyte membrane
stability and altered erythrocyte lifespan (ANK1, SPTA1)a n d
hemoglobin deglycation (FN3K) based on the known
function of the respective gene products mapping to the
vicinity of the association signals.
These patterns were confirmed in analyses conditioned
on fasting glucose or hematologic traits, which provided
statistical support for an effect on HbA1c via regulation of
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MTNR1B, and via hematologic parameters for HFE,
TMPRSS6, and HK1. Taken together, these results suggest
that these common variants influence HbA1c levels via
glycemic levels as well as erythrocyte physiology. Specific
mechanisms are suggested by existing knowledge on the
function of leading candidate genes in each region. These
hypotheses will need to be tested to understand mechanis-
tically and physiologically the effects of these genetic
variants.
Discovery Studies in Individuals with Diabetes
The GWAS described before were all carried out in healthy
individuals, using standardized analysis protocols and trait
definition. The strength of this approach is that association
results are not influenced by strong environmental con-
founders, principally disease status and antidiabetic medi-
cation. The observation that genetic associations underlying
HbA1c levels at some loci are independent from fasting
glucose reflects earlier observations in a classical discordant
Table 1 Summary of genetic variants robustly associated with HbA1c and correlated hematologic and metabolic traits in GWAS
Region Locus SNPs PubMed RAF β (95% CI)
a P Correlated trait association
b
1q23.1 SPTA1 rs2779116 20858683 0.27 0.02 (0.01–0.03)% increase 3×10
−9
2q31.1 G6PC2/ABCB11 rs1402837 19096518 0.23 0.02 (NR)% increase 5×10
−10 rs560887-FPG (18451265)
rs560887-FPG (19060907)
rs552976 20858683 0.64 0.05 (0.04–0.06)% increase 8×10
−18 rs563694-FPG (18521185)
rs560887-HOMA-B (20081858)
6p22.2 HFE rs1800562 20858683 0.94 0.06 (0.05–0.07)% increase 3×10
−20 rs1408272-MCH (19862010)
rs198846-Hgb (19820698)
7p13 GCK rs730497 19096518 0.17 0.03 (NR)% increase 6×10
−12 rs4607517-FPG (19060907)
rs4607517-HOMA-B (20081858) rs1799884 20858683 0.18 0.04 (0.03–0.05)% increase 1×10
−20
8p11.21 ANK1 rs6474359 20858683 0.97 0.06 (0.04–0.08)% increase 1×10
−8
rs4737009 20858683 0.24 0.03 (0.02–0.04)% increase 6×10
−12
8q24.11 SLC30A8 rs13266634 19096518 0.3 0.02 (NR)% decrease 5×10
−8 rs13266634-T2D (17293876, 17460697,
17463246, 17463248, 17463249, 19056611,
19401414), FPG (19734900)
rs3802177-T2D (20581827)
rs11558471-FPG (20081858)
10q22.1 HK1 rs16926246 20858683 0.9 0.09 (0.08–0.10)% increase 3×10
−54
rs7072268 19096518 0.5 0.05 (NR)% increase 2×10
−25
10q25.2 TCF7L2 rs7903146 20849430 0.72 0.05 (0.02–0.08)% HbA1c
decrease
1×10
−7 rs7901695-T2D (17463249)
rs4506565-FPG (20081858)
rs7903146-T2D (17293876, 17460697,
17463246, 17463248,17668382,
18372903, 19056611, 19401414,
19734900, 20581827)
rs12243326-OGTT (20081857)
11q14.3 MTNR1B rs1387153 20858683 0.28 0.03 (0.02–0.04)% increase 4×10
−11 rs1387153-T2D (20581827)
rs1387153-FPG (19060909)
rs2166706-FPG (19651812)
rs10830963-HOMA-B (20081858),
-FPG (19060907)
13q34 ATP11A/TUBGCP3 rs7998202 20858683 0.14 0.03 (0.02–0.04)% increase 5×10
−9
17q25.3 FN3K rs1046896 20858683 0.31 0.04 (0.03–0.05)% increase 2×10
−26
22q12.3 TMPRSS6 rs855791 20858683 0.42 0.03 (0.02–0.04)% increase 3×10
−14 rs855791-Hgb (19820698)
rs2413450-MCH (19862010)
Note that this table includes only results from GWAS studies, and intentionally omits candidate-SNP and candidate-gene studies
aNot reported
brsID, associated trait, PubMed ID; values are given for associations from genome-wide scans
FPG fasting plasma glucose; GWAS genome-wide association studies; HbA1c hemoglobin A1c; Hgb hemoglobin; HOMA homeostatic model
assessment; MCH mean corpuscular hemoglobin; OGTT oral glucose tolerance test; RAF risk allele frequency; SNP single nucleotide
polymorphism; T2D type 2 diabetes
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analysis revealed a significant correlation in HbA1c levels
in 45 MZ twins discordant for the disease (r=0.52, P<
0.001; as opposed to r=0.68, P<0.001 in 33 MZ twins
concordant for diabetes), suggesting that a substantial
proportion of heritability was due to diabetes-independent
familial effects. Although robust estimates of the proportion
of phenotypic variance attributable to diabetes-independent
genetic effects are still lacking, these results showed for the
first time that familial factors might explain variation in
HbA1c levels that is not dependent on glycemic control.
Recently, Paterson et al. [48￿] carried out a genome-wide
analysis on repeated measures of HbA1c from the DCCT
with the aim to identify genetic loci underlying glycemic
control in individuals with type 1 diabetes. The study sample
consisted of two sets of individuals sampled from the
conventional (n=667) and intensive (n=637) treatment
groups of the DCCT. Genome-wide SNPs were tested for
association with mean HbA1c, stratified by intervention arm
as well as in the combined cohort. This analysis yielded a
large number of SNPs (233) significant at the set threshold of
P=10
−4, indicating an excess of false-positive owing to
relatively underpowered study samples. Successive steps
were used to prioritize loci for replication, assessing the
association of these loci with capillary glucose and repeated
measures of multiple complications of diabetes. For replica-
tion, associations were assessed through a series of (non-
independent) analyses testing associations with quarterly
HbA1c using repeated measures, with mean daily glucose
and baseline C-peptide (to confirm a glycemic mechanism),
with HbA1c repeated measures in the combined cohort
(adjusting for treatment group and testing for interaction
with treatment), and with glycemic complications including
coronary calcium, neuropathy, hypoglycemia, and time to
renal or retinal complications (in each arm separately).
Loci having evidence for association after these steps,
including SNPs near SORCS1 at 10q25.1, GSC at 14q32.13,
BNC2 at 9p22, and WDR72 at 15q21.3, were carried forward
for replication in two independent replication samples. These
included the GoKinD study, a case–control collection of
patients with type 1 diabetes with and without diabetic
nephropathy, and healthy subjects from the MAGIC meta-
analysis described earlier. These analyses revealed a locus
(rs1358030 near SORCS1) where association reached the
widely accepted threshold for genome-wide significance of
P<5×10
−8 in the conventional treatment group, which was
also associated with mean glucose and showed suggestive
evidence for replication in the intensive treatment group and
in the control group in GoKinD. However, this association
was not seen among GoKinD participants with nephropathy
nor in the MAGIC sample. Another signal near BNC2
showed suggestive evidence in MAGIC but did not replicate
in GoKinD. SNPs in both regions were associated with
diabetes complications in the expected direction: SORCS1
with hypoglycemia (and less robustly with both retinopathy
and nephropathy) and BNC2 with microvascular end points.
It remains to be established if these variable replication
outcomes stem from limited study power, or reflect the
variable effect of the environment—most notably insulin
treatment—in the two study arms of the study. We direct the
readers to an accompanying editorial to the study [49]f o ra
more detailed exploration of these effects. A recent study
explored the same four loci BNC2, SORCS1, GSC, and
WDR72 for their effect on glycemic control in type 2
diabetes [50]. The authors typed 1486 subjects with type 2
diabetes from a Norwegian population-based cohort
(HUNT2), and tested their effects on HbA1c and non-
fasting glucose levels individually and in a combined genetic
score model. They detected no significant associations with
HbA1c or glucose and partially inconsistent direction of
associations. Further studies in other populations are needed
to identify whether genetic variants affect glycemic control
in type 1 and type 2 diabetes.
Impact of Genetic Discoveries on the Use of HbA1c
in Diabetes Monitoring, Diagnosis, and Treatment
in Europeans
Recently, an International Expert Committee has proposed a
revision of the diagnostic criteria for diabetes, recommending
thatHbA1c may be a better means of diagnosing diabetes than
measures of glucose (fasting and/or postchallenge) and that it
be adopted as a diagnostic criterion for diabetes [51]. The
2010 American Diabetes Association Standards of Medical
Care in Diabetes added the HbA1c ≥48 mmol/L (≥6.5%) as
another criterion for the diagnosis of diabetes [52]. The
recommendation is based on the association of microvascular
complications with HbA1c b e i n ga tl e a s ta ss t r o n ga st h o s e
with fasting or postchallenge glucose, that HbA1c is subject to
less day-to-day variability than fasting or postchallenge
glucose, and that it can be measured at any time of the day
without preparations such as fasting or a glucose challenge. It
is likely that practical, medical, methodologic, and financial
factors will prevent implementation of the recommendation in
the majority of clinical settings. It is nevertheless important to
understand how genetic factors underlying normal variation
in HbA1c through nonglycemic routes might influence
diabetes diagnosis.
In addition to severe pathologies characterized by altered
erythrocyte physiology (e.g., inherited hemoglobinopathies)
that may influence the utility of HbA1c in diabetes
diagnosis [31, 51, 53, 54], we and others showed that
genetically determined physiologic variation in the general
population can also play a role, affecting HbA1c levels
through subtler but more widespread alterations of iron
566 Curr Diab Rep (2011) 11:562–569levels and/or hemoglobin concentration. We sought to
quantify these genetic effects in population-level terms,
and to evaluate the resulting risk of misclassifying
individuals as diabetic or nondiabetic owing to genetic
influences on HbA1c. Using net reclassification analysis, we
estimated that the population-level impact of the seven
nonglycemic loci when HbA1c ≥6.5% is used as the
reference cutoff for diabetes diagnosis was approximately
2% (P=0.002). This estimate represents an upper boundary
for the effect of these common variants, as most people (the
majority in the center of the distribution) are expected to
have a smaller individual genotype effect size. This
suggests that variation in HbA1c levels due to common,
nonglycemic effect variants might influence only minimally
diagnosis or misclassification of diabetes.
Interethnic Differences in the Allelic Architecture
of HbA1c Levels and Their Impact on Diabetes
Diagnosis
HbA1c values are higher in African Americans than in the
population of European ancestry. Furthermore, variants at
loci controlling iron metabolism associated with HbA1c
levels are known to vary across ethnic groups. For instance,
the A allele frequency at rs1800562 (HFE) is absent in
populations of West African and East Asian ancestry (www.
hapmap.org) but is relatively common (~5%) in Europe.
The T allele at rs855791 (TMPRSS6) is at approximately
39% in Europeans, but relatively rare in West African
(~11%) and East Asian (~5%) populations. These observa-
tions raise the question of how variation in frequency and
effect size in diverse populations may affect reclassification
of diabetes status by HbA1c.
Althoughtheeffectofindividuallocihasnotbeenexplored,
Maruthur et al. [55￿] explored the contribution of inherited
interethnic differences in HbA1c levels in a cross-sectional
analysis of 2294 individuals of African American ancestry
from the community-based ARIC study. As rates of
admixture with Europeans vary among African Americans,
the percentage of European genetic ancestry for each
individual, estimated from ancestry-informative markers,
was compared with HbA1c levels categorized using American
Diabetes Association diagnostic cut points (<5.7, 5.7–6.4,
and ≥6.5%). This analysis showed that HbA1c levels were
positively correlated to the fraction of the genome that was of
European origin (P<0.001), although this correlation
accounted for a minimal fraction (<1%) of the overall
variability. Compared with genetic ancestry, socioeconomic,
demographic, and metabolic risk factors were estimated to
play a considerably greater role in governing changes in
HbA1c. As previously discussed for Europeans, these results
suggest that the inherited variability among populations is
likely to have a negligible impact on HbA1c-based diabetes
classification, and that the relative contribution of demo-
graphic and metabolic factors far outweighs the contribution
of genetic ancestry to HbA1c values in African Americans.
Conclusions and Outlook
Current evidence suggests that high-powered genetic analyses
provide important new opportunities for dissecting genetic
influencesofHbA1c levels. These initiatives will be important
not only to better understand genetic and biologic determi-
nants of HbA1c variation in the general population, but also to
inform recent initiatives to focus diabetes diagnosis and care
m o r ec e n t r a l l yo nH b A 1c. It will be of considerable interest in
the future to explore additional areas of study.
First, as more variants are discovered through sequenc-
ing and fine-mapping efforts, it will be important to
reassess genetic predisposition and reclassification rates in
European and non-European populations. Second, it will be
important to extend the study of genetic influences to
HbA1c in prediabetic and diabetic populations, although the
confounding effects of treatment might obscure any role of
these polymorphisms in the diabetic population. Finally,
additional genetic associations may be revealed from
studies of low-to-intermediate frequency variants through
imputation from the 1000 Genomes Project, direct associ-
ation using whole-genome sequencing data, and in-depth
replication and locus fine-mapping through custom arrays.
These hypothesis-generating genetic efforts will pave the
way for further studies of the role of the new loci in
hemoglobin glycation, glucose metabolism, and diabetes.
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